Eli Lilly and Nvidia have announced a partnership to build what they describe as the pharmaceutical industry\u2019s most powerful AI-driven supercomputer and \u201cAI factory.\u201d The goal is to transform how drugs are discovered and developed by reducing both time and cost. The new system is expected to be operational by January 2026, with potential returns projected toward the end of the decade.<\/p>\n\n\n\n
The effort represents a significant step forward for the use of artificial intelligence in life sciences. Drug development typically spans about ten years from the first human dose to commercial availability. With Nvidia\u2019s advanced GPUs and Eli Lilly\u2019s proprietary data, both companies hope to accelerate that timeline by several years.<\/p>\n\n\n\n
The supercomputer, operated and owned by Eli Lilly, will use more than 1,000 of Nvidia\u2019s latest Blackwell Ultra GPUs. These are connected through a high-speed, unified network designed to power an \u201cAI factory,\u201d a system that develops, trains, and deploys large-scale AI models specifically for pharmaceutical use.<\/p>\n\n\n\n
\u201cThis is like an enormous microscope for biologists,\u201d said Thomas Fuchs, Chief AI Officer at Eli Lilly. The new system allows researchers to train AI on millions of simulated experiments, expanding the potential for discovering new treatments and molecules previously out of reach.<\/p>\n\n\n\n
While there are currently no AI-designed drugs on the market, the number of candidates entering clinical trials is growing. The project may lay the foundation for wider adoption across the pharmaceutical sector in the coming years.<\/p>\n\n\n\n
Beyond internal use, Eli Lilly is offering access to its AI models through the TuneLab platform, launched in September. This initiative allows biotech companies to use AI models trained on Eli Lilly\u2019s research, valued at $1 billion. In return, participating companies contribute data to further train and refine the models using federated learning, ensuring that sensitive information remains secure.<\/p>\n\n\n\n
\u201cStartups often spend years building what TuneLab can now offer from day one,\u201d said Nvidia\u2019s Vice President of Healthcare Kimberly Powell. She emphasized that the initiative could shorten the development cycle for smaller companies, making cutting-edge research tools more accessible.<\/p>\n\n\n\n
The supercomputer will also support Eli Lilly\u2019s ambitions in precision medicine \u2014 an approach that customizes treatment based on a person\u2019s genetics, lifestyle, and environment. AI-driven tools will help researchers gain clearer insights into disease progression and identify new biomarkers for tailored treatments.<\/p>\n\n\n\n
\u201cWe want to deliver on the promise of precision medicine,\u201d Powell said. \u201cWithout a strong AI infrastructure, that future remains out of reach.\u201d Eli Lilly views this project as a foundation for longer-term innovation, even if the most meaningful outcomes may not be visible until 2030 or beyond.<\/p>\n\n\n\n
As AI capabilities advance and partnerships like this mature, the pharmaceutical industry could see fundamental changes in how medicines are developed, tested, and brought to market.<\/p>\n","protected":false},"excerpt":{"rendered":"
Partnership aims to accelerate drug development Eli Lilly and Nvidia have announced a partnership to build what they describe as the pharmaceutical industry\u2019s most powerful AI-driven supercomputer and \u201cAI factory.\u201d The goal is to transform how drugs are discovered and developed by reducing both time and cost. The new system is expected to be operational […]<\/p>\n","protected":false},"author":10772,"featured_media":12862,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[3197],"class_list":{"0":"post-12861","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-hns"},"_links":{"self":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts\/12861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/users\/10772"}],"replies":[{"embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12861"}],"version-history":[{"count":1,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts\/12861\/revisions"}],"predecessor-version":[{"id":12863,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/posts\/12861\/revisions\/12863"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=\/wp\/v2\/media\/12862"}],"wp:attachment":[{"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thetimesfinancial.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}